--FILE--Vista della gabbia di Jingxin Pharma durante una mostra a Shanghai in Cina, 13 aprile 2018. Il farmaco generico sviluppato da Zhejiang Jingxin P
--FILE--View of the stand of Jingxin Pharma during an exhibition in Shanghai, China, 13 April 2018. The generic drug developed by Zhejiang Jingxin Pharmaceutical to treat Alzheimer's disease has obtained the official approval document on drug registration issued by the China Food and Drug Administration. It is the first generic drug of its kind with an approval document number in China. The Xinchang-based company received the five-year approval for 1.5 milligram and 3 mg rivastigmine hydrogen tartrate capsules, it said in a statement yesterday. The rivastigmine hydrogen tartrate is a first-line drug developed by Swiss Novartis International to treat mild to moderate level of Alzheimer's disease. The drug was first released years ago. Jingxin Pharma is the first Chinese drug maker that has obtained the official approval document for this kind of medicine, the statement added.
